ENDRA Life Sciences (NDRA) Earning Somewhat Favorable News Coverage, Analysis Finds

Headlines about ENDRA Life Sciences (NASDAQ:NDRA) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. ENDRA Life Sciences earned a news impact score of 0.04 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.6570268704148 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Shares of ENDRA Life Sciences (NDRA) opened at $3.71 on Monday. ENDRA Life Sciences has a 52-week low of $2.15 and a 52-week high of $4.74.

COPYRIGHT VIOLATION NOTICE: This story was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2017/12/11/endra-life-sciences-ndra-earning-somewhat-favorable-news-coverage-analysis-finds.html.

About ENDRA Life Sciences

ENDRA Life Sciences Inc develops photo- and thermo-acoustic medical technologies that bring new capabilities to existing ultrasound systems. Its photo-acoustic solutions help global medical researchers to screen and modify disease models with high image quality and volume scanning speed. The company offers the Nexus-128 system, a fully 3D imaging solution for imaging anatomy, physiology, and labeled molecular targets for institutions.

Insider Buying and Selling by Quarter for ENDRA Life Sciences (NASDAQ:NDRA)

Receive News & Ratings for ENDRA Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply